194 related articles for article (PubMed ID: 25155936)
21. Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies.
Stamatoyannopoulos JA; Nienhuis AW
Annu Rev Med; 1992; 43():497-521. PubMed ID: 1374600
[TBL] [Abstract][Full Text] [Related]
22. Strategies to improve pharmacogenomic-guided treatment options for patients with β-hemoglobinopathies.
Patrinos GP; Chui DHK; Hardison RC; Steinberg MH
Expert Rev Hematol; 2021 Oct; 14(10):883-885. PubMed ID: 34490838
[TBL] [Abstract][Full Text] [Related]
23. Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy.
Tafrali C; Paizi A; Borg J; Radmilovic M; Bartsakoulia M; Giannopoulou E; Giannakopoulou O; Stojiljkovic-Petrovic M; Zukic B; Poulas K; Stavrou EF; Lambropoulou P; Kourakli A; Felice AE; Papachatzopoulou A; Philipsen S; Pavlovic S; Georgitsi M; Patrinos GP
Pharmacogenomics; 2013 Apr; 14(5):469-83. PubMed ID: 23556445
[TBL] [Abstract][Full Text] [Related]
24. Future prospects for treatment of hemoglobinopathies.
Stamatoyannopoulos JA
West J Med; 1992 Dec; 157(6):631-6. PubMed ID: 1282285
[TBL] [Abstract][Full Text] [Related]
25. Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment.
Singer ST; Kuypers FA; Olivieri NF; Weatherall DJ; Mignacca R; Coates TD; Davies S; Sweeters N; Vichinsky EP
Ann N Y Acad Sci; 2005; 1054():250-6. PubMed ID: 16339672
[TBL] [Abstract][Full Text] [Related]
26. Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin.
Bauer DE; Orkin SH
Curr Opin Genet Dev; 2015 Aug; 33():62-70. PubMed ID: 26375765
[TBL] [Abstract][Full Text] [Related]
27. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.
Banan M; Bayat H; Azarkeivan A; Mohammadparast S; Kamali K; Farashi S; Bayat N; Khani MH; Neishabury M; Najmabadi H
Hemoglobin; 2012; 36(4):371-80. PubMed ID: 22686296
[TBL] [Abstract][Full Text] [Related]
28. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.
Green NS; Ender KL; Pashankar F; Driscoll C; Giardina PJ; Mullen CA; Clark LN; Manwani D; Crotty J; Kisselev S; Neville KA; Hoppe C; Barral S
PLoS One; 2013; 8(2):e55709. PubMed ID: 23409025
[TBL] [Abstract][Full Text] [Related]
29. Genetic Basis and Genetic Modifiers of β-Thalassemia and Sickle Cell Disease.
Thein SL
Adv Exp Med Biol; 2017; 1013():27-57. PubMed ID: 29127676
[TBL] [Abstract][Full Text] [Related]
30. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
[TBL] [Abstract][Full Text] [Related]
31. Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the
Ghosh D; Panja A; Saha D; Banerjee U; Datta AK; Basu A
Genet Test Mol Biomarkers; 2021 Aug; 25(8):563-570. PubMed ID: 34406845
[No Abstract] [Full Text] [Related]
32. Reversing ontogeny.
Bunn HF
N Engl J Med; 1993 Jan; 328(2):129-31. PubMed ID: 7677964
[No Abstract] [Full Text] [Related]
33. Pharmacogenomics of hydroxyurea therapy and fetal hemoglobin levels in sickle cell anemia.
Sales RR; Nogueira BL; Luizon MR
Pharmacogenomics; 2022 May; 23(7):393-396. PubMed ID: 35546339
[No Abstract] [Full Text] [Related]
34. Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia?
Fathallah H; Sutton M; Atweh GF
Ann N Y Acad Sci; 2005; 1054():228-37. PubMed ID: 16339670
[TBL] [Abstract][Full Text] [Related]
35. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
36. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
[TBL] [Abstract][Full Text] [Related]
37. Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?
Banan M
Ann Hematol; 2013 Mar; 92(3):289-99. PubMed ID: 23318979
[TBL] [Abstract][Full Text] [Related]
38. Genetic association studies in β-hemoglobinopathies.
Thein SL
Hematology Am Soc Hematol Educ Program; 2013; 2013():354-61. PubMed ID: 24319204
[TBL] [Abstract][Full Text] [Related]
39. The search for genetic modifiers of disease severity in the β-hemoglobinopathies.
Lettre G
Cold Spring Harb Perspect Med; 2012 Oct; 2(10):. PubMed ID: 23028136
[TBL] [Abstract][Full Text] [Related]
40. Genetic predisposition to β-thalassemia and sickle cell anemia in Turkey: a molecular diagnostic approach.
Basak AN; Tuzmen S
Methods Mol Biol; 2011; 700():291-307. PubMed ID: 21204041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
